Results 81 to 90 of about 6,884,058 (284)
A European Consortium for Lysosomal Storage Diseases
Lysosomes are membrane-enclosed compartments, filled with hydrolytic enzymes that are used for the degradation of macromolecules. Proteins and other substrates are delivered to the lysosomes by various pathways including endocytosis, and autophagy, a ...
ANDRIA, GENEROSO
core
Lysosomal Lipid Storage Disease from the Perspective of General Pediatricians
Lizozomal lipid depo hastalıkları, lipid moleküllerinin katabolizmasında görevli enzimlerin eksikliği veya hücre içi taşınma kusurları sonucu meydana gelmektedir.
Ucar, Sema Kalkan +5 more
core +1 more source
Dual pKa Lipid Nanoparticles for Lung‐tropic mRNA Delivery and pH‐Programmed Endosomal Escape
Lipid nanoparticles’ bottleneck lies in low endosomal escape efficiency and liver‐dominant delivery after intravenous administration. To overcome these limitations, we present a stepwise pH‐programmed lipid nanoparticle system enabled by our newly synthesized ionizable lipid.
Seong Gi Lim +12 more
wiley +1 more source
Therapeutic approaches to Lysosomal Storage Disorders: the example of Pompe Disease [PDF]
Lysosomal Storage Disorders (LSDs) are different inherited diseases caused by the deficit of lysosomal or non-lysosomal proteins, resulting in the accumulation of undegraded substrates in lysosomes.
Annunziata, Fabio
core +1 more source
Macrophage RSAD2 dually regulates CMPK2—the rate‐limiting enzyme for mitochondrial DNA synthesis—by suppressing its ubiquitination and promoting its phosphorylation via Csnk2a2 recruitment. This amplifies mtDNA production, which simultaneously activates a cGAS‐STING‐IRF3‐RSAD2 feedforward loop and the NLRP3 inflammasome, driving a self‐sustaining ...
Haomiao Yuan +16 more
wiley +1 more source
This graphical abstract illustrates how chaperone‐mediated autophagy (CMA) regulates intervertebral disc degeneration (IDD). Under normal homeostasis (B), CMA degrades cytoplasmic Midnolin (MIDN) to maintain proteostasis. Under inflammatory stress (A), impaired CMA leads to cytoplasmic MIDN accumulation.
Xianglong Chen +9 more
wiley +1 more source
Lysosomal storage disease 2 - Pompe's disease
Pompe's disease, glycogen-storage disease type II, and acid maltase deficiency are alternative names for the same metabolic disorder. It is a pan-ethnic autosomal recessive trait characterised by acid alpha-glucosidase deficiency leading to lysosomal ...
van der Ploeg, Ans T. +1 more
core +1 more source
Diagnosis of Lysosomal Storage Diseases in Romanian Patients
As an important group among inherited metabolic disorders, lysosomal storage diseases represent a major healthcare concern. To date, more than 40 different lysosomal storage diseases, characterised by the deficiency of a lysosomal protein, have been ...
Cristiana DRUGAN +5 more
doaj
Lysosomal storage diseases are a group of inherited and acquired disorders. They are characterized by interruption of recycling of cellular and extracellular molecules. Clinically, they are presented as developmental and neurological symptoms similar to other inherited and acquired disorders.
Alroy, Joseph, Lyons, Jeremiah A.
openaire +4 more sources
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source

